GLP-1 Drug Prescriptions Rise Among Postpartum Women in New US Study

A new cross-sectional study published in JAMA examines how often commercially insured women in the United States begin taking glucagon-like peptide-1, or GLP-1, receptor agonists after giving birth. The research, led by corresponding author Sih-Ting Cai, PhD, of the University of Southern California’s Schaeffer Center for Health Policy, arrives at a moment when these medications have become some of the most discussed and most prescribed drugs in American medicine, and when clinicians are increasingly weighing their role in one of the most physiologically complex periods of a woman’s life: the months following childbirth.

GLP-1 receptor agonists are a class of drugs originally developed to treat type 2 diabetes. They mimic the action of glucagon-like peptide-1, a hormone released by the intestine after eating that stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on brain regions that regulate appetite and satiety. Semaglutide and tirzepatide, the best-known members of the class, have demonstrated dramatic effects on body weight in large clinical trials, and their approval for chronic weight management has transformed the treatment landscape for obesity. That transformation has inevitably raised questions about which patient populations might benefit, and the postpartum period has emerged as one of the most debated frontiers.

Pregnancy and the postpartum interval represent a distinctive metabolic transition. During gestation, the body deliberately develops a degree of insulin resistance to shunt nutrients toward the fetus, and most women retain a substantial portion of their pregnancy weight gain after delivery. Postpartum weight retention is common, and for a subset of women it contributes to long-term weight trajectories that raise the risk of type 2 diabetes, cardiovascular disease, and other chronic conditions. Women who experienced gestational diabetes or hypertensive disorders of pregnancy face particularly elevated long-term risks, which is why the postpartum visit has long been viewed by obstetricians and primary care physicians as a critical window for preventive counseling and intervention.

Until recently, the pharmacological toolkit for postpartum weight management was limited. Older weight-loss medications carried safety concerns that made them unsuitable for breastfeeding mothers, and lifestyle counseling alone has historically produced modest and often unsustainable results. The arrival of highly effective GLP-1 receptor agonists has changed the calculus, but it has also generated genuine uncertainty. Lactation compatibility remains incompletely characterized for some agents, manufacturers’ labeling has evolved, and professional societies have issued cautious guidance emphasizing shared decision-making between clinicians and new mothers. Against that backdrop, real-world prescribing data offer a valuable window into how practice is actually changing.

That is precisely the gap the JAMA study addresses. By analyzing commercial insurance claims, the researchers were able to identify women in the postpartum period and measure how frequently they initiated a GLP-1 receptor agonist prescription. Cross-sectional designs of this kind cannot establish causation or track individual trajectories over time, but they are well suited to capturing a snapshot of prescribing behavior across a large, nationally representative slice of the privately insured population. Because commercial claims data link diagnoses, deliveries, and dispensed prescriptions, they allow researchers to distinguish postpartum initiation from GLP-1 use that began before pregnancy or for indications such as diabetes treatment.

The commercial insurance focus matters for interpreting the findings. GLP-1 receptor agonists are expensive, with list prices that have strained both insurers and patients, and coverage decisions vary widely across plans. Employer-sponsored insurance, which covers a majority of non-elderly Americans, has become the primary route through which many women access these drugs, and prior authorization requirements, step therapy protocols, and exclusion policies for weight-management indications all shape who ultimately fills a prescription. A study confined to commercially insured women therefore captures the population most likely to encounter these medications, while leaving open questions about access among Medicaid beneficiaries and the uninsured, groups that include a disproportionate share of births in the United States.

The timing of the study is also significant. Prescriptions for GLP-1 receptor agonists have surged nationwide over the past several years, driven by clinical trial evidence, direct-to-consumer advertising, telehealth platforms, and growing public awareness of obesity as a treatable chronic disease. Obstetric care has not been immune to this trend. Postpartum visits, typically scheduled four to six weeks after delivery, increasingly include conversations about long-term weight and cardiometabolic health, and some clinicians have begun to consider pharmacotherapy alongside the traditional recommendations for breastfeeding, physical activity, and dietary change. Whether that shift is reflected in measurable prescribing patterns is exactly the kind of question claims-based research can answer.

Beyond the headline numbers, the study raises broader issues that the authors and commentators are likely to explore in the months ahead. One is safety and guidance: professional organizations have generally advised careful individualized assessment of GLP-1 therapy during lactation, weighing the benefits of treatment against limited data on drug transfer into breast milk and effects on infant growth. Another is equity: if postpartum GLP-1 initiation is concentrated among commercially insured women, the medications may widen existing disparities in obesity care rather than narrow them. A third is indication: distinguishing prescriptions written for weight management from those written for diabetes or other approved uses is essential for understanding what the prescribing patterns actually represent.

There are also scientific questions that claims data alone cannot resolve. Randomized trials of GLP-1 receptor agonists specifically in postpartum populations remain scarce, and the long-term effects of these drugs on lactation, fertility during the interpregnancy interval, and subsequent pregnancy outcomes are still being studied. Researchers have noted that the postpartum period is a time of rapid hormonal change, sleep disruption, and high caregiving demands, all of which can influence adherence to any medication regimen. Real-world adherence to GLP-1 therapy is known to be imperfect across populations, and new mothers may face particular barriers related to cost, side effects such as nausea, and the logistical demands of infant care.

What the JAMA study ultimately provides is a rigorous baseline. By quantifying GLP-1 receptor agonist initiation among postpartum women with commercial insurance in the United States, it establishes a reference point against which future trends can be measured as labeling evolves, as clinical trial evidence accumulates, and as coverage policies shift. For clinicians, the findings underscore the importance of evidence-based counseling at the postpartum visit; for policymakers, they highlight the intersection of drug pricing, insurance design, and maternal health; and for researchers, they mark the beginning of a much-needed conversation about how the most consequential weight-management therapies of the era fit into the care of women after childbirth. The study, published in JAMA with the corresponding author based at the USC Schaeffer Center for Health Policy, is a reminder that the GLP-1 revolution is no longer confined to endocrinology clinics and celebrity headlines. It is reaching into obstetrics, one prescription at a time, and the medical community is only beginning to understand what that means for the health of mothers in the years after delivery.

Subject of Research: Postpartum initiation of GLP-1 receptor agonist prescriptions among commercially insured women in the United States

Article Title: Postpartum initiation of GLP-1 receptor agonists among commercially insured women in the us

Article References: Postpartum initiation of GLP-1 receptor agonists among commercially insured women in the us. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: GLP-1 receptor agonists, postpartum care, obesity, commercial insurance, prescription trends, maternal health, semaglutide, tirzepatide, weight management, JAMA, health policy, lactation